Comparison
While Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480, Setmelanotide is approved for chronic weight management in patients with POMC, PCSK1, LEPR deficiencies and Bardet–Biedl syndrome by reducing hunger and promoting weight loss92.
While Semaglutide works as a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480, Setmelanotide is a potent synthetic melanocortin-4 receptor (MC4R) agonist derived from a POMC/α-MSH–related sequence that restores downstream MC4R signaling in genetic obesity syndromes3192100.
Semaglutide is 31 amino acids long, whereas Setmelanotide is shorter as it has a length of amino acids. Semaglutide is made up of a sequence of sequence data not available in the current dataset. Setmelanotide is made up of a sequence of sequence data not available in the current dataset.
Semaglutide
GCG
Setmelanotide
POMC